← Browse by Condition
Medical Condition

non small cell lung cancers

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1
NCT06130254 Phase 1
Recruiting

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Enrollment
52 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →